BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genzyme Corporation (GENZ) Fabrazyme Shortage to Worsen


3/24/2011 7:20:19 AM

Boston Business Journal -- Genzyme Corp. (Nasdaq: GENZ) has announced that new problems at its beleaguered Allston plant will further aggravate a shortage of its drug Fabrazyme, to treat the rare genetic disorder, Fabry disease.

Patients, some of whom have been receiving only half of their usual doses, may now have to skip or delay a dose of the drug over the next few months, Genzyme said.

In a message to patients, the Cambridge, Mass.-based biotechnology company said that a problem with the last step of the manufacturing process, called fill/finish, where the medicine is put into vials and labeled, has caused a batch of medicine to be rejected. The news comes as the company is still trying to recover from a shortage of the product that began almost two years ago, after the Allston plant was closed for six weeks during the summer of 2009, following the discovery of a virus.

Fill/finish problems have long plagued Genzyme, and a serious enforcement action by the U.S. Food and Drug Administration last year, called a Consent Decree, ordered the company to cease all fill/finish operations in Allston. Genzyme has to date transferred most of those functions to a contract manufacturer, and said it will send all Fabrazyme fill/finish work to the contractor from here on out.

Genzyme told patients that the company is still on track to return to normal dosing of the drug during the second half of 2011, when a new facility in Framingham, Mass. is expected to be approved by the FDA.

Genzyme’s shares were trading at $75.60 in afternoon trading Wednesday, down slightly from $75.66 at the previous close. Genzyme agreed to be bought by French drug maker Sanofi-Aventis Feb. 16 for $20.1 billion.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES